Acute Kidney Injury On the FDA label for Ozempic, acute kidney injury and worsening of chronic renal failure is listed as a potential adverse reaction
Before the lag time, 12% of the thyroid cancer group and 9.6% of the control group used GLP-1 receptor agonists, with more than 80% in both groups using liraglutide (Victoza, Novo Nordisk)
Examples include anticholinergic medications and opioid pain medications (e.g., hydrocodone, morphine) Metabolism and clearance Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety and amide hydrolysis DOSING Dosage forms Single-dose pen and single-dose vials 2.5 mg/0.5 ml 5 mg/0.5 ml 7.5 mg/0.5 ml 10 mg/0.5 ml 12.5 mg/0.5 ml 15 mg/0.5 ml Kwikpen (each pen contains 4 doses) 4 doses of 2.5 mg: 10 mg/2.4 mL (4.17 mg/mL) 4 doses of 5 mg: 20 mg/2.4 mL (8.33 mg/mL) 4 doses of 7.5 mg: 30 mg/2.4 mL (12.5 mg/mL) 4 doses of 10 mg: 40 mg/2.4 mL (16.7 mg/mL) 4 doses of 12.5 mg: 50 mg/2.4 mL (20.8 mg/mL) 4 doses of 15 mg: 60 mg/2.4 mL (25 mg/mL) Multi-dose vial (each vial contains 4 doses) 4 doses of 2.5 mg/0.6 mL: 10 mg/2.4 mL (4.17 mg/mL) 4 doses of 5 mg/0.6 mL: 20 mg/2.4 mL (8.33 mg/mL) 4 doses of 7.5 mg/0.6 mL: 30 mg/2.4 mL (12.5 mg/mL) 4 doses of 10 mg/0.6 mL: 40 mg/2.4 mL (16.7 mg/mL) 4 doses of 12.5 mg/0.6 mL: 50 mg/2.4 mL (20.8 mg/mL) 4 doses of 15 mg/0.6 mL: 60 mg/2.4 mL (25 mg/mL) Dosing (adults and pediatric patients aged 10 - 17 years) Starting: 2.5 mg subcutaneously once weekly
Antihypertensive Effect of Glucagon-Like Peptide 1 in Dahl Salt-Sensitive Rats
Resources Peer-Reviewed Research Bartel, McElroy, Levangie & Keshen (2024) Use of glucagon-like peptide-1 receptor agonists in eating disorder populations, International Journal of Eating Disorders Radkhah et al
In this GLP-1 round up: New research confirms up to 40% of GLP-1 weight loss may come from lean mass Insurance changes are disrupting access and driving up patient costs Tech-enabled care models deliver better adherence and real-world results Next-generation therapies and oral options are reshaping the treatment landscape Table of Contents Muscle Loss and GLP-1s: What We Knowand What You Can Do GLP-1s remain highly effective for weight loss, but accumulating research shows a significant portion of weight lost may come from lean musclenot just fat
